Exousia Bio Income Statement

Financials in millions USD. Fiscal year is June - May.

Millions USD. Fiscal year is Jun - May.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Nov '25 Nov 30, 2025	May '25 May 31, 2025	May '24 May 31, 2024	May '23 May 31, 2023	May '22 May 31, 2022
Revenue	-	0	0.01	-	-
Revenue Growth	-	-67.39%	-	-	-
Cost of Revenue	0.07	0.01	0.01	-	-
Gross Profit	-0.07	-0	0	-	-
Selling, General & Admin	0.05	0.03	0.03	0.04	0
Operating Expenses	0.22	0.03	0.03	0.05	0
Operating Income	-0.28	-0.03	-0.03	-0.05	-0
Interest Expense	-	-	-	-0.01	-0
Other Non Operating Income (Expenses)	-0.01	0.09	0	-	-
EBT Excluding Unusual Items	-0.29	0.05	-0.03	-0.06	-0
Asset Writedown	-0	-0	-	-	-
Pretax Income	-0.08	0.05	-0.03	-0.06	-0
Net Income	-0.08	0.05	-0.03	-0.06	-0
Net Income to Common	-0.08	0.05	-0.03	-0.06	-0
Net Income Growth	-	-	-	-	-
Shares Outstanding (Basic)	10	8	8	6	2
Shares Outstanding (Diluted)	10	8	8	6	2
Shares Change	33.89%	-	36.77%	248.82%	-
EPS (Basic)	-0.01	0.01	-0.00	-0.01	-
EPS (Diluted)	-0.01	0.01	-0.00	-0.01	-
EPS Growth	-	-	-	-	-

Additional Metrics

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Nov '25 Nov 30, 2025	May '25 May 31, 2025	May '24 May 31, 2024	May '23 May 31, 2023	May '22 May 31, 2022
Gross Margin	-	-93.36%	15.94%	-	-
Operating Margin	-	-850.16%	-228.20%	-	-
Profit Margin	-	1370.53%	-224.41%	-	-
EBITDA	-0.28	-0.02	-0.01	-0.04	-0
EBITDA Margin	-	-	-100.37%	-	-
D&A For EBITDA	0	0.01	0.01	0.01	0
EBIT	-0.28	-0.03	-0.03	-0.05	-0
EBIT Margin	-	-	-228.20%	-	-